Clinical trial
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor…
NCT00170846 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00170846 |
|---|---|
| Title | ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients |
| Official title | Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus (RAD001), Calcineurin Inhibitors (CNI), Mycophenolate acid (MPA)/Azathioprine (AZA), Steroids |
| Enrollment | 394 |
| Start date | Feb 1, 2005 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 27, 2015 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: